Skip to main content
Glama

Chembl

by io.github.pipeworx-io

Entity Profile

entity_profile
Read-onlyIdempotent

"Tell me about X" / "research Acme" / "brief me on Tesla" / "what does Apple do" / "company profile for Microsoft" / "give me the rundown on NVDA" / "everything you know about $TICKER" — full cross-source profile of a US public company in ONE parallel call. ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view. Fans out across SEC EDGAR, XBRL, USPTO patents, federal contracts (USAspending), FDA-licensed biologics (Purple Book), H-1B hiring (DOL LCA), news and GLEIF, and returns: cik + company_name (+ resolved_from/resolved_to when value was a name); recent_filings (up to 5 with pipeworx://edgar/company/{cik}/filings/{accession} URIs); fundamentals (LATEST 10-K Revenues + NetIncomeLoss + Cash, sorted period_end DESC); patents (USPTO PatentsView API sunset May 2025 — soft-fails until reactivated); federal_contracts (USAspending awards where the company is the recipient); fda_products (FDA-licensed biologics — vaccines, cell/gene therapies — from the Purple Book; a company with only small-molecule/generic drugs will show none here, that is expected, not a failure); hiring (H-1B sponsorship volume + salary range from DOL LCA filings); recent news mentions via GDELT→GNews fallback; LEI via GLEIF. sources_used / sources_failed say which of these actually returned data for THIS company — an empty section is a real "no data", not a bug. Pass a ticker ("AAPL"), zero-padded CIK ("0000320193"), OR a company name ("Moderna") — names now resolve via SEC EDGAR's company-name match; a private company (no CIK/ticker) returns resolved:false with an explicit notes line, not a bare failure. type accepts "company" or "ticker" interchangeably — both take the same value shapes above.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYes"company" or "ticker" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon.
valueYesTicker (e.g., "AAPL"), zero-padded CIK (e.g., "0000320193"), or company name (e.g., "Moderna") — names resolve via SEC EDGAR company-name match.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed3 schema fields changed
    • changedInput schema / properties / type / description
      Previous value: -"Entity type. Only \"company\" supported today; person/place coming soon."New value: +"\"company\" or \"ticker\" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon."
    • changedInput schema / properties / type / enum
      Previous value: -[
-  "company"
-]New value: +[
+  "company",
+  "ticker"
+]
    • changedInput schema / properties / value / description
      Previous value: -"Ticker (e.g., \"AAPL\") or zero-padded CIK (e.g., \"0000320193\"). Names not supported — use resolve_entity first if you only have a name."New value: +"Ticker (e.g., \"AAPL\"), zero-padded CIK (e.g., \"0000320193\"), or company name (e.g., \"Moderna\") — names resolve via SEC EDGAR company-name match."
  2. First observed

TDQS

A4.8/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond readOnlyHint/idempotentHint, the description discloses soft-failure behavior (USPTO sunset), explains that empty fda_products is expected for small-molecule companies, and clarifies that empty sources are real 'no data' rather than errors. It also documents the resolved:false path for private companies.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long, but front-loaded with usage signal and organized as a dense list of sources and return fields. Every clause adds functional detail, though the volume of caveats makes it less immediately scannable than a short tool description.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Despite having no output schema, the description enumerates the return structure (cik, company_name, recent_filings with URIs, fundamentals, patents, federal_contracts, fda_products, hiring, news, LEI) and failure modes, so an agent can anticipate the full response. It even covers edge cases like private companies and source outages.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100% for both parameters, and the description restates and enriches that with examples ('AAPL', '0000320193', 'Moderna') and the fact that names resolve via SEC EDGAR. It clarifies type interchangeability but does not add entirely new semantic detail beyond the schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with concrete query examples and defines the tool as a 'full cross-source profile of a US public company', giving a specific verb (profile) and resource (company). It differentiates from single-pack lookups by naming the holistic fan-out across SEC, XBRL, patents, contracts, FDA, H-1B, news, and GLEIF.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It explicitly states 'ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view', providing a clear condition for use. It also explains acceptable inputs and how private companies are handled, so an agent knows when not to expect a full profile.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Chembl toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

B3.4/5.0
Disambiguation2/5

The tool list mixes a small ChEMBL dataset with a large Pipeworx toolkit, and several Pipeworx tools are near-duplicates (ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded; polymarket_arbitrage, polymarket_edges, polymarket_fill_risk). An agent would struggle to pick the right tool among overlapping prediction-market and research tools, and the ChEMBL tools are buried under irrelevant functionality.

Naming Consistency2/5

Naming conventions are mixed: ChEMBL tools use bare nouns (molecule, target, activities) while Pipeworx tools use inconsistent verb_noun phrases (ask_pipeworx, validate_claim) and noun phrases (entity_profile, recent_changes). There is no predictable pattern across the set.

Tool Count2/5

37 tools is far too many for a server named 'Chembl', especially since the majority are unrelated Pipeworx features. The count is justified neither by the apparent ChEMBL scope nor by a coherent overall purpose, making the server feel bloated and unfocused.

Completeness3/5

The ChEMBL subset is reasonably complete (search, molecule, target, activities, mechanism, drug_indications), and the Pipeworx side includes broad research/data tools, but the set lacks a unified purpose. Gaps include no direct assay/detail retrieval and no coherent lifecycle across the mixed domains.

Resources